{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:26Z","timestamp":1787009006341,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Natalizumab, a monoclonal IgG4 antibody used in the treatment of multiple sclerosis (MS), inhibits \u03b14\u03b21 (very late antigen-4, VLA-4)\u2013binding to vascular cell adhesion molecule-1 (VCAM-1), thereby reducing leukocyte recruitment to inflamed tissues. The intricate mechanisms underlying these effects remain unclear, particularly concerning the heavy-chain shuffling of IgG4. We conducted an in vitro study to quantify the impact of bivalent IgG and monovalent Fab forms of natalizumab on the capture and migration of human primary memory T lymphocytes under shear stress, using VCAM-1 and CXCL12-coated surfaces. IgG natalizumab at concentrations near its cell surface EC50 (half-maximal effective concentration) showed significant of capture and resistance of adherent cells to shear stress, whereas significantly higher doses of Fab natalizumab, up to 100-fold greater than its cell surface EC50, were needed to achieve similar effects. These findings highlight that receptor occupancy alone may not adequately predict the functional outcomes of inhibitor antibodies. For optimal therapeutic effect, inhibition of cell-surface adhesion may require specific kinetic and geometric binding properties of antibodies.<\/jats:p>\n                  <jats:p>Insight Box This study shows how natalizumab functionally inhibits \u03b14\u03b21 (very late antigen-4, VLA-4)\u2013mediated T-cell adhesion by integrating quantitative affinity measurements with dynamic assays performed under shear stress. We show that the antibody\u2019s bivalency provides a major functional advantage, enabling strong inhibition of cell capture and adhesion at concentrations near its EC50 (half-maximal effective concentration), whereas monovalent Fab fragments require 10- to 100-fold higher doses. These findings offer biological insight into why receptor occupancy alone cannot predict adhesion inhibition. By combining cell-based affinity quantification with real-time adhesion and migration assays, our work reveals how kinetic and geometric properties of antibody\u2013integrin interactions shape immune cell dynamics, informing the rational design of next-generation integrin-targeting therapeutics.<\/jats:p>","DOI":"10.1093\/intbio\/zyag015","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:53:25Z","timestamp":1784807605000},"source":"Crossref","is-referenced-by-count":1,"title":["Bivalency of natalizumab promotes inhibition of dynamic VLA-4 adhesion beyond affinity gain"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6031-3813","authenticated-orcid":false,"given":"Marie-Pierre","family":"Valignat","sequence":"first","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, LAI , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Biarnes-Pelicot","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, LAI , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Touchard","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, LAI , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rico-Lamy","sequence":"additional","affiliation":[{"name":"Timone Hosp, AP-HM, Pole Neurosci Clin, Serv Neurol , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6104-6286","authenticated-orcid":false,"given":"Patrick","family":"Chames","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Theodoly","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, LAI , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Robert","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, CNRS, INSERM, LAI , Marseille ,","place":["France"]},{"name":"Timone Hosp, Dept Immunol , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"2026073115025261000_ref1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"2026073115025261000_ref2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1084\/jem.177.1.57","article-title":"Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma","volume":"177","author":"Baron","year":"1993","journal-title":"J Exp Med"},{"key":"2026073115025261000_ref3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/archneur.59.3.391","article-title":"Migration of multiple sclerosis lymphocytes through brain endothelium","volume":"59","author":"Prat","year":"2002","journal-title":"Arch Neurol"},{"key":"2026073115025261000_ref4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"2026073115025261000_ref5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"2026073115025261000_ref6","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med"},{"key":"2026073115025261000_ref7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","article-title":"Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"key":"2026073115025261000_ref8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1191\/1352458505ms1205oa","article-title":"Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis","volume":"11","author":"O\u2019Connor","year":"2005","journal-title":"Mult Scler"},{"key":"2026073115025261000_ref9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2026073115025261000_ref10","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.4049\/jimmunol.0803418","article-title":"Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis","volume":"182","author":"Coisne","year":"2009","journal-title":"J Immunol"},{"key":"2026073115025261000_ref11","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.1021\/ac402237v","article-title":"Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 fab arm exchange and \u201cbispecific\u201d monoclonal antibody formation","volume":"85","author":"Debaene","year":"2013","journal-title":"Anal Chem"},{"key":"2026073115025261000_ref12","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange","volume":"317","author":"Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"2026073115025261000_ref13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1046\/j.1365-2567.1999.00845.x","article-title":"Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites","volume":"97","author":"Schuurman","year":"1999","journal-title":"Immunology"},{"key":"2026073115025261000_ref14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in fab-arm exchange with endogenous human IgG4 in vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol"},{"key":"2026073115025261000_ref15","doi-asserted-by":"publisher","first-page":"32314","DOI":"10.1074\/jbc.M113.501668","article-title":"How Natalizumab binds and antagonizes \u03b14 Integrins*","volume":"288","author":"Yu","year":"2013","journal-title":"J Biol Chem"},{"key":"2026073115025261000_ref16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2012.00242","article-title":"Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion","volume":"3","author":"Chigaev","year":"2012","journal-title":"Front Immunol"},{"key":"2026073115025261000_ref17","doi-asserted-by":"publisher","first-page":"38174","DOI":"10.1074\/jbc.M210472200","article-title":"Alpha4beta1 integrin affinity changes govern cell adhesion","volume":"278","author":"Chigaev","year":"2003","journal-title":"J Biol Chem"},{"key":"2026073115025261000_ref18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1182\/blood.V96.2.506.014k41_506_513","article-title":"VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrin-dependent leukocyte adhesion involving the urokinase receptor","volume":"96","author":"May","year":"2000","journal-title":"Blood"},{"key":"2026073115025261000_ref19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1084\/jem.175.4.1045","article-title":"Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein","volume":"175","author":"Nojima","year":"1992","journal-title":"J Exp Med"},{"key":"2026073115025261000_ref20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1084\/jem.192.4.495","article-title":"Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions","volume":"192","author":"Grabovsky","year":"2000","journal-title":"J Exp Med"},{"key":"2026073115025261000_ref21","doi-asserted-by":"publisher","first-page":"625366","DOI":"10.3389\/fbioe.2021.625366","article-title":"Functional mapping of adhesiveness on live cells reveals how guidance phenotypes can emerge from complex spatiotemporal integrin regulation","volume":"9","author":"Robert","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"2026073115025261000_ref22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bjh.14158","article-title":"VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow","volume":"174","author":"White","year":"2016","journal-title":"Br J Haematol"},{"key":"2026073115025261000_ref23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood.V124.21.221.221","article-title":"Natalizumab blocks VLA-4 mediated red blood cell adhesion and is a potential therapy for sickle cell disease","volume":"124","author":"Hines","year":"2014","journal-title":"Blood"},{"key":"2026073115025261000_ref24","doi-asserted-by":"publisher","first-page":"21053","DOI":"10.1074\/jbc.M116.733709","article-title":"Lateral mobility and nanoscale spatial arrangement of chemokine-activated \u03b14\u03b21 Integrins on T cells","volume":"291","author":"Sosa-Costa","year":"2016","journal-title":"J Biol Chem"},{"key":"2026073115025261000_ref25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12195-018-0519-x","article-title":"An experimentally determined state diagram for human CD4+ T lymphocyte CXCR4-stimulated adhesion under shear flow","volume":"11","author":"Anderson","year":"2018","journal-title":"Cell Mol Bioeng"},{"key":"2026073115025261000_ref26","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1529\/biophysj.104.045690","article-title":"Molecular basis for the dynamic strength of the integrin alpha4beta1\/VCAM-1 interaction","volume":"87","author":"Zhang","year":"2004","journal-title":"Biophys J"},{"key":"2026073115025261000_ref27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.bpj.2019.12.013","article-title":"A Bistable mechanism mediated by Integrins controls Mechanotaxis of leukocytes","volume":"118","author":"Hornung","year":"2020","journal-title":"Biophys J"},{"key":"2026073115025261000_ref28","doi-asserted-by":"publisher","first-page":"jcs242883","DOI":"10.1242\/jcs.242883","article-title":"Lymphocytes perform reverse adhesive haptotaxis mediated by LFA-1 integrins","volume":"133","author":"Luo","year":"2020","journal-title":"J Cell Sci"},{"key":"2026073115025261000_ref29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/385537a0","article-title":"Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness","volume":"385","author":"Palecek","year":"1997","journal-title":"Nature"},{"key":"2026073115025261000_ref30","first-page":"4157","article-title":"Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays","volume":"52","author":"Kaufman","year":"1992","journal-title":"Cancer Res"},{"key":"2026073115025261000_ref31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.19.1.397","article-title":"Chemokine Signaling and functional responses: the role of receptor dimerization and TK pathway activation","volume":"19","author":"Mellado","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"2026073115025261000_ref32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/eji.1830270632","article-title":"Clustering the adhesion molecules VLA-4 (CD49d\/CD29) in Jurkat T cells or VCAM-1 (CD106) in endothelial (ECV 304) cells activates the phosphoinositide pathway and triggers Ca2+ mobilization","volume":"27","author":"Ricard","year":"1997","journal-title":"Eur J Immunol"},{"key":"2026073115025261000_ref33","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.V87.5.1855.1855","article-title":"Stimulation of tyrosine phosphorylation after ligation of beta7 and beta1 integrins on human B cells","volume":"87","author":"Manie","year":"1996","journal-title":"Blood"},{"key":"2026073115025261000_ref34","first-page":"273","article-title":"Ligation of members of the beta 1 or the beta 2 subfamilies of integrins by antibodies triggers eosinophil respiratory burst and spreading","volume":"80","author":"Laudanna","year":"1993","journal-title":"Immunology"},{"key":"2026073115025261000_ref35","doi-asserted-by":"publisher","first-page":"C990","DOI":"10.1152\/ajpcell.00481.2001","article-title":"Clustering of very late antigen-4 integrins modulates K(+) currents to alter Ca(2+)-mediated monocyte function","volume":"283","author":"Colden-Stanfield","year":"2002","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026073115025261000_ref36","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1074\/jbc.272.15.10287","article-title":"VLA-4 integrin cross-linking on human monocytic THP-1 cells induces tissue factor expression by a mechanism involving mitogen-activated protein kinase","volume":"272","author":"McGilvray","year":"1997","journal-title":"J Biol Chem"},{"key":"2026073115025261000_ref37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1042\/BJ20130485","article-title":"CD25 and CD69 induction by \u03b14\u03b21 outside-in signalling requires TCR early signalling complex proteins","volume":"454","author":"Cimo","year":"2013","journal-title":"Biochem J"},{"key":"2026073115025261000_ref38","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2026073115025261000_ref39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026073115025261000_ref40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ijbiomac.2018.07.141","article-title":"Boosting half-life and effector functions of therapeutic antibodies by fc-engineering: an interaction-function review","volume":"119","author":"Fonseca","year":"2018","journal-title":"Int J Biol Macromol"}],"container-title":["Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyag015\/70416782\/zyag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ib\/article-pdf\/doi\/10.1093\/intbio\/zyag015\/70416782\/zyag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:02:57Z","timestamp":1785524577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ib\/article\/doi\/10.1093\/intbio\/zyag015\/8748605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/intbio\/zyag015","relation":{},"ISSN":["1757-9708"],"issn-type":[{"value":"1757-9708","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"zyag015"}}